Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
medication
|
| gptkbp:activeDuring |
leuprolide acetate
|
| gptkbp:administrativeDivision |
monthly
every 6 months every 3 months |
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:availableIn |
generic version
|
| gptkbp:brand |
gptkb:Lupron_Injection
gptkb:Lupron_Depot gptkb:Lupron_Depot-PED |
| gptkbp:clinicalTrials |
palliative care
Phase II short-term treatment Phase III Phase I long-term treatment |
| gptkbp:commonName |
11.25 mg every 3 months
22.5 mg every 6 months 3.75 mg monthly |
| gptkbp:contraindication |
pregnancy
breastfeeding hypersensitivity to leuprolide |
| gptkbp:dosageForm |
solution for injection
|
| gptkbp:drugInterdiction |
metabolized in the liver
half-life of approximately 3 hours peak plasma concentration in 1-2 hours |
| gptkbp:hasPopulation |
adult men
adult women children with precocious puberty |
| gptkbp:healthcare |
discuss risks with healthcare provider
monitor for signs of adrenal insufficiency report any unusual symptoms immediately |
| https://www.w3.org/2000/01/rdf-schema#label |
Lupron Injection
|
| gptkbp:interactsWith |
anticoagulants
hormonal therapies antidiabetic medications |
| gptkbp:lastProduced |
1985
|
| gptkbp:manufacturer |
AbbVie
|
| gptkbp:route |
intramuscular injection
subcutaneous injection |
| gptkbp:sideEffect |
fatigue
nausea weight gain injection site reactions mood changes hot flashes |
| gptkbp:storage |
store at room temperature
|
| gptkbp:triggerType |
gonadotropin-releasing hormone agonist
|
| gptkbp:usedFor |
treating endometriosis
treating precocious puberty treating prostate cancer |
| gptkbp:waterManagement |
primarily through urine
minimal fecal excretion |